RxDoctor Payments Data

Bernice Acevedo, MD

Nephrology · Miami, FLNPI 1801117726

Payments from drug & device makers

$5,945in general payments, 2019–2025

Across 234 payments — averaging $25.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$580
  • Bayer$577
  • Vifor Pharma, Inc.$556
  • Mallinckrodt Hospital Products Inc.$446
  • Aurinia Pharma U.S., Inc.$357
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$5,77697%
  • Education$1693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,945 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$199,686
Medicare patients
491
Services billed
1,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol234$155,345
KerendiaFinerenone80$57,154
OzempicSemaglutide44$57,021
MounjaroTirzepatide45$50,085
LokelmaSodium Zirconium Cyclosilicate32$36,426
VeltassaPatiromer Calcium Sorbitex31$32,476
ProcritEpoetin Alfa49$27,795
AranespDarbepoetin Alfa In Polysorbat14$24,394
RybelsusSemaglutide12$23,591
RetacritEpoetin Alfa-Epbx26$19,035
Xigduo XrDapaglifloz Propaned/Metformin31$18,687
JardianceEmpagliflozin20$15,160
VascepaIcosapent Ethyl18$8,230
Cinacalcet Hcl16$1,230
Losartan Potassium64$690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,431$191,771266 claims
Novo NordiskOzempic, Rybelsus$580$80,61256 claims
BayerKerendia$577$57,15480 claims
Lilly USA, LLCMounjaro$81$50,08545 claims
AmgenAranesp$275$24,39414 claims
Boehringer IngelheimJardiance$84$15,16020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →